Silence Therapeutics plc
SLNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSilence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of. With a market capitalization of $324.0M, it sits in small-cap territory. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Market Cap
$324.0M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-17.59
EPS (TTM)
$-1.62
EPS (Fwd)
$-0.39
ROE
-92.6%
ROA
-29.8%
Cash
$70.1M
Total Debt
$136,000
Free CF
-$44.6M
52W Change
17.5%
Annual Financials
Cash vs Debt
Silence Therapeutics plc holds $70.1M in cash against $136K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$44.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -92.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $21.7M to $559K.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing SLN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.